What is Roivant?
Founded in 2014 and headquartered in London, Roivant Sciences operates as a tech-enabled healthcare enterprise. The company distinguishes itself through a specialized focus on the acquisition and development of promising late-stage drug candidates. By integrating data-driven insights with traditional pharmaceutical research, Roivant aims to bridge the gap between clinical potential and patient access. Its market position is defined by a portfolio-based strategy that mitigates the risks typically associated with drug discovery while maximizing the efficiency of clinical trials and commercialization efforts.
How much funding has Roivant raised?
Roivant has raised a total of $1.4B across 3 funding rounds:
Private Equity
$100M
Private Equity
$1.1B
Private Equity
$200M
Private Equity (2014): $100M with participation from Dexcel Pharma and QVT Financial
Private Equity (2017): $1.1B led by Dexcel Pharma and Softbank
Private Equity (2018): $200M supported by NovaQuest Capital Management and RTW Investments
Key Investors in Roivant
Softbank
A global technology holding company that drives innovation across AI, robotics, and IoT, leveraging its Vision Fund to scale transformative businesses worldwide.
RTW Investments
A life sciences investment firm specializing in biotech and medtech innovation, supporting companies from inception through to public market maturity.
Dexcel Pharma
Israel’s largest privately owned pharmaceutical company, focused on the development and commercialization of branded prescription drugs and OTC products.
What's next for Roivant?
Looking ahead, the strategic deployment of $200M is expected to accelerate the maturation of Roivant's diverse pipeline. As the company scales, the focus will likely shift toward optimizing its proprietary technology platforms to further streamline the development lifecycle of its therapeutic assets. With strong institutional support from global investors, Roivant is well-equipped to navigate the complexities of the modern biotech landscape, potentially expanding its footprint in both therapeutic innovation and digital health solutions. The firm's ability to maintain this momentum will be critical as it transitions toward broader commercialization and long-term value creation for stakeholders.
See full Roivant company page
